MARINUS PHARMACEUTICALS INC's ticker is MRNS and the CUSIP is 56854Q101. A total of 26 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2016. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $332,000 | -81.8% | 80,000 | -94.0% | 0.04% | -85.5% |
| Q2 2017 | $1,824,000 | -22.6% | 1,331,421 | 0.0% | 0.31% | -32.8% |
| Q1 2017 | $2,357,000 | +74.1% | 1,331,421 | -0.7% | 0.46% | +34.4% |
| Q4 2016 | $1,354,000 | -44.5% | 1,340,588 | 0.0% | 0.34% | -13.6% |
| Q3 2016 | $2,440,000 | +64.1% | 1,340,588 | +14.5% | 0.40% | +2.8% |
| Q2 2016 | $1,487,000 | -51.6% | 1,170,643 | +105.0% | 0.39% | -42.0% |
| Q1 2016 | $3,071,000 | -29.6% | 570,908 | 0.0% | 0.67% | +4.2% |
| Q4 2015 | $4,362,000 | +222.6% | 570,908 | +252.2% | 0.64% | +271.5% |
| Q3 2015 | $1,352,000 | -61.0% | 162,120 | -45.7% | 0.17% | -49.3% |
| Q2 2015 | $3,463,000 | +80.4% | 298,533 | +39.8% | 0.34% | +69.5% |
| Q1 2015 | $1,920,000 | -37.9% | 213,533 | -27.3% | 0.20% | -62.0% |
| Q4 2014 | $3,094,000 | +62.9% | 293,533 | 0.0% | 0.53% | +124.3% |
| Q3 2014 | $1,899,000 | – | 293,533 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 3,977,453 | $15,194,000 | 8.96% |
| Granite Point Capital Management, L.P. | 2,638,321 | $10,078,000 | 0.98% |
| New Leaf Venture Partners, L.L.C. | 342,550 | $1,309,000 | 0.71% |
| 683 Capital Management, LLC | 1,200,000 | $4,584,000 | 0.40% |
| Virtus ETF Advisers LLC | 80,389 | $307,000 | 0.27% |
| Iguana Healthcare Management, LLC | 100,000 | $382,000 | 0.25% |
| THREE BAYS CAPITAL LP | 944,300 | $3,607,000 | 0.25% |
| Granite Point Capital Management, L.P. | 549,900 | $2,101,000 | 0.20% |
| Cormorant Asset Management, LP | 478,111 | $1,826,000 | 0.14% |
| GMT CAPITAL CORP | 2,533,798 | $9,680,000 | 0.12% |